Clinical trial · Interventional
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06508775CI-TRIAL-00097953LONGSAFErecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphatic Leukemia | Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| B-cell Non Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Non-Hodgkin Lymphoma | Childhood Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Chronic Lymphatic Leukemia | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| Melanoma Stage III | Melanoma | CURATED_BROADER | 0.78 |
| Melanoma Stage IV | Melanoma | CURATED_BROADER | 0.78 |
| Pediatric ALL | Childhood Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MB-CART19.1 | Biological | — | UNRESOLVED |
| MB-CART20.1 | Biological | — | UNRESOLVED |
| MB-CART2019.1 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Long-term follow-up of CAR T cell therapy
- description
- Assessment of long-term safety and efficacy of Miltenyi CAR T treatment.
- interventionNames
- Biological: MB-CART19.1
- Biological: MB-CART20.1
- Biological: MB-CART2019.1
Primary outcomes (1)
- measure
- Adverse Events
- timeFrame
- through study completion, up to 14 years
- description
- Percentage of patients with late-onset adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR) and adverse events of special interest (AESI) including relapse or progression of the underlying disease, life-threatening infections, death due to any cause, new and secondary malignancies
Secondary outcomes (8)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up. * Patient has provided informed consent prior to enrollment. Exclusion Criteria: * No exclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.